Motilal Oswal expects Emcure to deliver a revenue CAGR of 15.2% over FY26-28E, driven by stable growth across segments, with domestic formulation and international business projected to grow at a CAGR of 12.4% and 17.4%, respectively.
Motilal Oswal expects Emcure to deliver a revenue CAGR of 15.2% over FY26-28E, driven by stable growth across segments, with domestic formulation and international business projected to grow at a CAGR of 12.4% and 17.4%, respectively.
<iframe src="https://hindustansphere.com/embed/cluster/3fb15e71e904666a5e0758e6a1f7a2ce2b6929b0" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Emcure Pharma Shares May Rally Up To 33%, Says MOFSL On Strong Growth Outlook; Check Target Price"></iframe>
